Alembic's ANDA Approval for Doxil Generic Boosts Market Growth

  Published 1 year ago

Alembic's ANDA, approved liposomal doxorubicin matches Doxil, treating cancers with $29M market potential. The company now has 224 USFDA approvals, including 201 final and 23 tentative.

  • Treats ovarian cancer, AIDS, related Kaposi's sarcoma, and multiple myeloma with strong demand.
  • Vertically integrated R&D firm with global generic drug manufacturing and marketing.
  • Facilities approved by the USFDA and other developed nations' agencies for quality assurance.

You might like these

M&M Boosts Stake in MMFSL, Shares Rise to 52.49%

Royal Orchid Hotels Rises on New Property Launch in Solapur

Schneider India CFO Resigns

India's Services Exports Rise 12% in June

Paper Stocks Rally on DGFT Import Floor

Vintage Coffee Expands Capacity with New Investment

AI Deal Worth Rs 450 Crore

News that matters the most ⚡